抗体
试剂盒
多肽
蛋白
组织芯片
产品中心
Product Center
| 货号 | 名称 | 纯度 | CAS号 | 分子式 | 分子量 |
| TD-AP459131 | CD40靶向肽：KGYY15 | 95% 或98%可选 | 1690215-31-6 | C₈₄H₁₂₉N₂₁O₂₂S₁ | 1817.12 |
| TD-AP181272 | 线粒体靶向肽、抗菌肽：(KLAKLAK)2 | 95%、98% | 184240-26-4 | C₇₂H₁₃₈N₂₀O₁₅ | 1523.99 |
| TD-AP514908 | Cu(2+) 离子亲和肽：LI-18 | 95% 或98%可选 | 222557-92-8 | C₉₄H₁₆₀N₃₂O₂₂ | 2090.48 |
| TD-AP208736 | p32靶向肽：Lin TT1 | C₃₆H₆₈N₁₆O₁₂ | 917.03 | ||
| TD-AP436632 | HER2阳性肿瘤靶向肽、归巢肽：LTVSPWY | C₄₃H₆₀N₈O₁₁ | 864.98 | ||
| TD-AP537807 | 肿瘤淋巴管靶向肽：LyP-2 | 95% 或98%可选 | C₃₇H₆₇N₁₇O₁₂S₂ | 1006.16 | |
| TD-AP204769 | 清道夫受体A（SR-A）靶向肽、M2型巨噬细胞靶向肽：M2pep | C₈₃H₁₀₁N₁₇O₂₀ | 1656.79 | ||
| TD-AP203393 | c-MET靶向肽：Met-pep1 | C₇₄H₁₀₄N₁₆O₁₅ | 1457.72 | ||
| TD-AP407986 | 线粒体靶向肽：MLC | C₁₀₃H₁₄₆N₂₄O₁₈S₂ | 2072.54 | ||
| TD-AP110276 | E75, Her-2/neu(369-377)、HER2靶向肽：Nelipepimut-S | 95%、98% | 160212-35-1 | C₅₀H₇₈N₁₀O₁₁ | 995.21 |
| TD-AP434468 | 肿瘤靶向前凋亡肽、Tumor Targeted Pro-Apoptotic Peptide、NGR Peptide 1 | 1926163-30-5 | C₉₄H₁₇₄N₃₂O₂₂S₂ | 2168.72 | |
| TD-AP467233 | IL13RA2受体靶向肽：NOTA-Pep-1L | 95% 或98%可选 | C₈₄H₁₃₉N₂₇O₂₅S₃ | 2023.36 | |
| TD-AP563384 | CD11c靶向肽：P-D2 | 95% 或98%可选 | C₆₅H₉₈N₁₆O₂₁ | 1439.57 | |
| TD-AP534869 | TIM3靶向肽：P26 | 95% 或98%可选 | C₅₈H₁₀₁N₁₅O₁₅S₁ | 1280.58 | |
| TD-AP530445 | PC-3肿瘤靶向肽：LSNNNLR | 95% 或98%可选 | C₃₃H₅₉N₁₃O₁₂ | 829.9 | |
| TD-AP568343 | PD-L1 inhibitory peptide | 1931111-41-9 | C₉₆H₁₃₅N₂₁O₂₃S | 1983.3 | |
| TD-AP432287 | CXCR4靶向肽：Pentixafor | 1341207-62-2 | |||
| TD-AP500099 | 葡萄糖调节蛋白78(GRP78)靶向肽：Pep42 | 95% 或98%可选 | C₅₈H₉₄N₁₆O₁₆S₂ | 1335.59 | |
| TD-AP452190 | MDM2和MDMX靶向肽：Phage-derived 12/1 peptide | 95% 或98%可选 | 186180-20-1 | C₇₁H₉₉N₁₇O₁₉S₂ | 1558.78 |
| TD-AP453970 | Tenascin-C靶向肽：PL3 | 95% 或98%可选 | C₃₆H₆₉N₁₇O₉ | 884.04 |